Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial.
Saved in:
| Title: | Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. |
|---|---|
| Authors: | Mo ZJ; Expanded Program on Immunization Department, Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China., Bi ZF; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Sheng W; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Chen Q; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Huang T; Expanded Program on Immunization Department, Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China., Li MQ; Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China., Cui XL; Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China., Wangjiang YH; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Lin BZ; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China., Zheng FZ; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China., Sun G; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China., Li YF; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Zheng Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Zhuang SJ; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Su YY; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Pan HR; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China., Huang SJ; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Wu T; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Zhang J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Xia NS; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Nov 30; Vol. 18 (6), pp. 2092363. Date of Electronic Publication: 2022 Jul 14. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2164-554X |
|---|---|
| DOI: | 10.1080/21645515.2022.2092363 |
